M Holdings Securities Inc. Decreases Position in Amgen, Inc. (AMGN)

M Holdings Securities Inc. lessened its position in shares of Amgen, Inc. (NASDAQ:AMGN) by 12.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,456 shares of the medical research company’s stock after selling 357 shares during the quarter. M Holdings Securities Inc.’s holdings in Amgen were worth $478,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Oregon Public Employees Retirement Fund lifted its stake in shares of Amgen by 20,103.6% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 31,424,215 shares of the medical research company’s stock worth $161,000 after acquiring an additional 31,268,677 shares during the last quarter. BlackRock Inc. raised its position in Amgen by 2.0% during the 4th quarter. BlackRock Inc. now owns 46,127,396 shares of the medical research company’s stock valued at $8,979,621,000 after purchasing an additional 906,568 shares in the last quarter. Geode Capital Management LLC raised its position in Amgen by 5.8% during the 4th quarter. Geode Capital Management LLC now owns 8,850,224 shares of the medical research company’s stock valued at $1,720,250,000 after purchasing an additional 482,760 shares in the last quarter. Epoch Investment Partners Inc. raised its position in Amgen by 536.5% during the 4th quarter. Epoch Investment Partners Inc. now owns 524,376 shares of the medical research company’s stock valued at $102,080,000 after purchasing an additional 441,995 shares in the last quarter. Finally, Northern Trust Corp raised its position in Amgen by 4.7% during the 4th quarter. Northern Trust Corp now owns 9,182,050 shares of the medical research company’s stock valued at $1,787,470,000 after purchasing an additional 408,675 shares in the last quarter. Institutional investors and hedge funds own 80.00% of the company’s stock.

Several research firms have recently commented on AMGN. Zacks Investment Research lowered Amgen from a “buy” rating to a “hold” rating in a research report on Wednesday, January 23rd. Goldman Sachs Group reissued a “buy” rating and issued a $232.00 price target on shares of Amgen in a research report on Thursday, January 17th. Oppenheimer set a $224.00 price target on Amgen and gave the stock a “buy” rating in a research report on Sunday, January 27th. Royal Bank of Canada reissued a “neutral” rating and issued a price target on shares of Amgen in a research report on Monday, January 14th. Finally, Citigroup boosted their target price on Amgen from $204.00 to $210.00 and gave the stock a “neutral” rating in a research note on Friday, January 4th. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating and nine have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $208.84.

Amgen stock opened at $176.50 on Friday. The company has a current ratio of 2.79, a quick ratio of 2.57 and a debt-to-equity ratio of 2.36. The stock has a market cap of $110.45 billion, a price-to-earnings ratio of 12.26, a PEG ratio of 2.20 and a beta of 1.15. Amgen, Inc. has a fifty-two week low of $165.22 and a fifty-two week high of $210.19.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, April 30th. The medical research company reported $3.56 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $3.45 by $0.11. The business had revenue of $5.56 billion for the quarter, compared to the consensus estimate of $5.55 billion. Amgen had a return on equity of 67.08% and a net margin of 34.00%. The company’s quarterly revenue was up .1% compared to the same quarter last year. During the same quarter in the previous year, the business earned $3.47 EPS. On average, research analysts forecast that Amgen, Inc. will post 13.95 earnings per share for the current year.

The company also recently declared a quarterly dividend, which will be paid on Friday, June 7th. Shareholders of record on Friday, May 17th will be paid a dividend of $1.45 per share. The ex-dividend date is Thursday, May 16th. This represents a $5.80 annualized dividend and a yield of 3.29%. Amgen’s payout ratio is presently 40.28%.

In other Amgen news, Director Ronald D. Sugar sold 2,000 shares of the business’s stock in a transaction dated Wednesday, March 6th. The stock was sold at an average price of $188.88, for a total transaction of $377,760.00. Following the sale, the director now owns 14,988 shares in the company, valued at approximately $2,830,933.44. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website . In the last quarter, insiders have sold 6,000 shares of company stock worth $1,144,120. Company insiders own 0.25% of the company’s stock.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company’s products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells. Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN) Receive News & Ratings for Amgen Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Amgen and related companies with MarketBeat.com’s FREE daily email newsletter .

Click Here to Continue...